Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides

Clinical Cancer Research

Volumn 9, Issue 8, 2003, Pages 3142-3149

  Köchling, Joachim ^a,b   König Merediz, Sven A ^c   Stripecke, Renata ^d   Buchwald, Dirk ^b   Korte, Alexander ^b   Von Einsiedel, Hagen G ^b   Sack, Florian ^e   Henze, Günter ^b   Seeger, Karl ^b   Wittig, Burghardt ^c,e   Schmidt, Manuel ^c  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c MOLOGEN AG   (Germany)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 2; OLIGONUCLEOTIDE; RETROVIRUS VECTOR; VACCINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER REGRESSION; CELL PROTECTION; CONTROLLED STUDY; ELECTROPORATION; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION SYSTEM; GENE TRANSFER; GENETIC TRANSFECTION; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; MOUSE; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; VACCINATION;

AMINO ACID MOTIFS; ANIMALS; BASE SEQUENCE; CANCER VACCINES; CELL LINE; CELL LINE, TUMOR; CPG ISLANDS; DISEASE-FREE SURVIVAL; ELECTROPORATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDES; RETROVIRIDAE; TIME FACTORS; TRANSFECTION; TRANSGENES; TUMOR CELLS, CULTURED;

EID: 12444329763     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Arico, M., Valsecchi, M. G., Camitta, B., Schrappe, M., Chessells, J., Baruchel, A., Gaynon, P., Silverman, L., Janka Schaub, G., Kamps, W., Pui, C. H., and Masera, G. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N. Engl. J. Med., 342: 998-1006, 2000.
2. Chen, C. H., and Wu, T. C. Experimental vaccine strategies for cancer immunotherapy. J. Biomed. Sci., 5: 231-252, 1998.
3. Restifo, N. P., and Rosenberg, S. A. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr. Opin. Oncol., 11: 50-57, 1999.
4. Hirano, N., Takahashi, T., Ohtake, S., Hirashima, K., Emi, N., Saito, K., Hirano, M., Shinohara, K., Takeuchi, M., Taketazu, F., Tsunoda, S., Ogura, M., Omine, M., Saito, T., Yazaki, Y., Ueda, R., and Hirai, H. Expression of costimulatory molecules in human leukemias. Leukemia (Baltimore), 10: 1168-1076, 1996.
5. Schwartz, R. H. A cell culture model for T lymphocyte clonal anergy. Science (Wash. DC), 248: 1349-1356, 1990.
6. Conry, R. M., Widera, G., LoBuglio, A. F., Fuller, J. T., Moore, S E., Barlow, D. L., Turner, J., Yang, N. S., and Curiel, D. T. Selected strategies to augment polynucleotide immunization. Gene Ther., 3: 67-74, 1996.
7. Boussiotis, V. A., Barber, D. L., Nakarai T., Freeman, G. J., Gribben, J. G., Bernstein, G. M., D'Andrea, A. D., Ritz, J., and Nadler, L. M. Prevention of T cell anergy by signaling through the γ c chain of the IL-2 receptor. Science (Wash. DC), 266: 1039-1042, 1994.
8. Matulonis, U. A., Dosiou, C., Lamont, C., Freeman, G. J., Mauch, P., Nadler, L. M., and Griffin, J. D. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 85: 2507-2515, 1995.
9. Arceci, R. J. The potential for antitumor vaccination in acute myelogenous leukemia. J. Mol. Med., 76: 80-93 1998.
10. Stripecke, R., Skelton, D. C., Gruber, T., Afar, D., Pattengale, P. K., Witte O. N., and Kohn, D. B. Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther., 9: 2049-2062, 1998.
11. Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J. L., Fraser, C. C., Cavazzana-Calvo, M., and Fischer, A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 348: 255-256, 2003.
12. Schmidt Wolf, I. G., Huhn, D., Neubauer, A. and Wittig, B. Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma. Hum. Gene Ther., 5: 1161-1168, 1994.
13. Wittig, B., Märten, A., Dorbic, T., Weirneck, S., Min, H., Niemitz, S., Trojaneck, B., Flieger, D., Kruopis, S., Albers, A., Löffel, A., Albers, P., Müller, S., Sauerbruch, T., Bieber, T., Huhn, D., and Schmidt-Wolf, I. G. H. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immuno-modified autologous tumor cells: a first clinical phase I/II trial. Hum. Gene Ther., 12: 267-278, 2001.
14. Mahvi, D. M., Sondel, P. M., Yang, N. S., Albertini, M. R., Schiller, J. H., Hank, J., Heiner, J., Gan, J., Swain, W., and Logrono, R. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum. Gene Ther., 8: 875-891, 1997.
15. Sun, Y., Jurgovsky, K., Moller, P., Alijagic, S., Dorbic, T., Georgieva, J., Wittig, B., and Schadendorf, D. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther., 5: 481-490, 1998.
16. Schakowski, F., Gorschlüter, M., Junghans, C., Schroff, M., Buttgereit, P., Ziske, C., Schöttker, B., König-Merediz, S. A., Sauerbruch, T., Wittig, B., and Schmidt-Wolf, I. G. H. X novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol. Ther., 3: 793-800, 2001.
17. Boretti, F. S., Leutenegger, C. M., Mislin, C., Hofmann-Lehmann, R., Konig, S., Schroff, M., Junghans, C., Fehr, D., Huettner, S. W., Habel, A., Flynn, J. N., Aubert, A., Pedersen, N. C., Wittig, B., and Lutz, H. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression. Aids, 14: 1749-1457, 2000.
18. Messina, J. P., Gilkeson, G. S., and Pisetsky, D. S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol. 147: 1759-1764, 1991.
19. Krieg, A. M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol., 20: 709-760, 2002.
20. Jakob, T., Walker, P. S., Krieg, A. M., Udey, M. C., and Vogel, J. C. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J. Immunol., 161: 3042-3049, 1998.
21. Tidd, D. M., Spiller, D. G., Broughton, C. M., Norbury, L. C., Clark, R. E., and Giles, R. V. Oligodeoxynucleotide 5mers containing a 5′-CpG induce apoptosis through a mitochondrial mechanism in T lymphocytic leukaemia cells. Nucleic Acids Res., 28: 2242-2250, 2000.
22. Roman, M., Martin-Orozco, E., Goodman, J. S., Nguyen, M. D., Sato, Y., Ronaghy, A., Kornbluth, R. S., Richman, D. D., Carson, D. A., and Raz, E. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat. Med., 3: 849-854, 1997.
23. Sandler, A. D., Chihara, H., Kobayashi, G., Zhu, X., Miller, M. A., Scott, D. L., and Krieg, A. M. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res., 63: 394-399, 2003.
24. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
25. Stripecke, R., Skelton, D. C., Pattengale, P. K., Shimada, H., and Kohn, D. B. Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia. Hum. Gene Ther., 10: 2109-2122, 1999.
26. Weiner, G. J., Liu, H. M., Wooldridge, J. E., Dahle, C. E., and Krieg, A. M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA, 94: 10833-10837, 1997.
27. Schmidt, M., Nagel, S., Proba, J., Thiede, C., Ritter, M., Waring, J. F., Rosenbauer, F., Huhn, D., Wittig, B., Horak, I., and Neubauer, A. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood, 91: 22-29, 1998.
28. Koenig Merediz, S. A., Schmidt, M., Hoppe, G. J., Alfken, J., Meraro, D., Levi, B. Z., Neubauer, A., and Wittig, B. Cloning of an interferon regulatory factor 2 isoform with different regulatory ability. Nucleic Acids Res., 28: 4219-4224, 2000.
29. Manabe, A., Murti, K. G., Coustan Smith, E., Kumagai, M., Behm, F. G., Raimondi, S. C., and Campana, D. Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood, 83: 758-766, 1994.
30. Dilloo, D., Rill, D., Entwistle, C., Boursnell, M., Zhong, W., Holden, W., Holladay, M., Inglis, S., and Brenner, M. A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood, 89: 119-127, 1997.
31. Mascarenhas, L., Stripecke, R., Case, S. S., Xu, D., Weinberg, K. I., and Kohn, D. B. Gene delivery to human B-precursor acute lymphoblastic leukemia cells. Blood, 92: 3537-3545, 1998.
32. Miller, A. D. Human gene therapy comes of age. Nature (Lond.), 357: 455-460, 1992.
33. Brenner, M. K., Rill, D. R., Moen, R. C., Krance, R. A., Mirro, J., Jr., Anderson, W. F., and Ihle, J. N. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet, 341: 85-86, 1993.
34. Chen, L., Ashe, S., Brady, W. A., Hellstrom, I., Hellstrom, K. E., Ledbetter, J. A., McGowan, P., and Linsley, P. S. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell, 71: 1093-1102, 1992.
35. Townsend, S. E., and Allison, J. P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (Wash. DC), 259: 368-370, 1993.
36. Larchian, W. A., Horiguchi, Y., Nair, S. K., Fair, W. R., Heston, W. D., and Gilboa, E. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. Clin. Cancer Res., 6: 2913-2920, 2000.
37. Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., and Frost, P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60: 397-403, 1990,
38. Chen, S. A., Tsai, M. H., Wu, F. T., Hsiang, A., Chen, Y. L., Lei, H. Y., Tzai, T. S., Leung, H. W., Jin, Y. T., Hsieh, C. L., Hwang, L. H., and Lai, M. D. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine. Clin. Cancer Res., 6: 4381-4388, 2000.
39. Markowicz, S., and Engleman, E. G. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J. Clin. Investig., 85: 955-961, 1990.
40. Levitsky, H. I., Montgomery, J., Ahmadzadeh, M., Staveley O'Carroll, K., Guarnieri, F., Longo, D. L., and Kwak, L. W. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol., 156: 3858-3865, 1996.
41. Dunussi-Joannopoulos, K., Dranoff, G., Weinstein, H. J., Ferrara, J. L., Bierer, B. E., and J. M., C. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood, 91: 222-230, 1998.
42. Tani, K., Nakazaki, Y., Hase, H., Takahashi, K., Azuma, M., Ohata, J., Kitamura, R., Komine, F., Oiwa, M., Masunaga, A., Maekawa, T., Satoh, N., Adachi, D., Soda, Y., Machida, U., Endo, M., Yamazaki, T., Watari, K., Tojo, A., Yamashita, N., Tomikawa, S., Eriguchi, M., Hamada, H., Wakumoto, Y., Hanazawa, K., and Okumura, K. Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer cells. Cancer Chemother. Pharmacol., 46 (Suppl.): S73-S76, 2000.
43. Jaffee, E. M., Hruban, R. H., Biedrzycki, B., Laheru, D., Schepers, K., Sauter, P. R., Goemann, M., Coleman, J., Grochow, L., Donehower, R. C., Lillemoe, K. D., O'Reilly, S., Abrams, R. A., Pardoll, D. M., Cameron, J. L., and Yeo, C. J. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J. Clin. Oncol., 19: 145-156, 2001.
44. Hodi, F. S., Schmollinger, J. C., Soiffer, R. J., Salgia, R., Lynch, T., Ritz, J., Alyea, E. P., Yang, J., Neuberg, D., Mihm, M., and Dranoff, G. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc. Natl. Acad. Sci. USA, 99: 6919-6924, 2002.
45. Bird, A. P. DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Res., 8: 1499-1504, 1980.
46. Zimmermann, S., Egeter, O., Hausmann, S., Lipford, G. B., Rocken, M., Wagner, H., and Heeg, K. CpG oligodeoxynucleotides trigger protective,and curative Th1 responses in lethal murine leishmaniasis. J. Immunol., 160: 3627-3630, 1998.
47. Matzinger, P. Tolerance, danger, and the extended family. Annu. Rev. Immunol., 12: 991-1045, 1994.
48. Brown B. D., and Lillicrap D. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. Blood, 100: 1133-1140, 2002.